Emerging research on dual and triple agonists The success of GLP-1 agonists has led to research on new drugs that can target two or three points at the same time
Incretin action of GIP is dramatically reduced in the presence of diabetes, as demonstrated by the evidence that glucose-dependent insulin secretion is not potentiated by GIP administration in subjects with diabetes [33, 34]
Yet no matter which one you choose, we aim to come alongside you in your weight loss journey so that you can feel more confident, one step at a time
If a prescription GLP-1 medication is right for you, a provider can walk you through the process and help you get started safely and effectively
Generally, candidates have a specific Body Mass Index (BMI), often 30 or greater, or 27 or greater with a weight-related condition like high blood pressure